Certainly, future modifications of NPs–EUG, such as replacement of casein with fibronectin, a known in vivo MMP-7 substrate [98], can open other administration routes besides IV, such as direct injection into the tumor mass under colonoscopy guides. The gene discussed is FN1; the disease is neoplasm.